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I. SUMMARY 
Background 
BMS-986001 is a thymidine analogue nucleoside reverse transcriptase inhibitor (NRTI) designed 
to maintain the in vitro antiviral activity demonstrated by other NRTIs, whilst minimising off-
target effects. This study assessed efficacy and safety of BMS-986001 versus tenofovir disoproxil 
fumarate (TDF) in treatment-naïve, HIV-1-infected subjects. 
Methods 
AI467003 was a Phase 2b, randomised, active-controlled, blinded-to-BMS-986001 dose trial. 
HIV-1-infected adults with plasma HIV-1 RNA greater than 5000 copies per mL and CD4+ T-cell 
counts greater than 200 cells/mm3 were randomised 2:2:2:3 to three BMS-986001 arms (100, 200 
or 400 mg once daily), or reference arm (TDF 300 mg once daily), each with efavirenz (600 mg 
once daily) and lamivudine (300 mg once daily). Both subjects and investigators remained 
blinded to BMS-986001 dose, but not allocation, through Week 48. Proportion of subjects with 
plasma HIV-1 RNA less than 50 copies per mL and safety (serious adverse events [SAEs] and 
AEs leading to discontinuation) through Week 24 were primary endpoints. Resistance analysis 
was a secondary endpoint, and additional safety parameters were exploratory endpoints. 
AI467003 is registered with ClinicalTrials.gov (NCT01489046). 
Findings 
A total of 757 subjects were assessed for eligibility and 301 randomised. Randomised subjects 
were assigned to receive either BMS-986001 (n=67 for the 100 mg once-daily group, n=67 for the 
200 mg once-daily group, n=66 for the 400 mg once-daily group) or TDF (n=101). 297 subjects 
received at least one dose of study drug. At Week 24, 57 (88%) of out 65 subjects in the 100 mg 
once-daily group, 54 (81%) of 67 subjects in the 200 mg once-daily group, 62 (94%) of 66 
subjects in the 400 mg once-daily group achieved HIV-1 RNA less than 50 copies per mL, 
compared with 88 (89%) out of 99 subjects in the TDF group (modified intent-to-treat 
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population). BMS-986001 was generally well tolerated through Week 48. Two subjects had 
BMS-986001-related SAEs (atypical drug eruption and thrombocytopenia) and two subjects in 
the TDF arm had study drug-related SAEs (potential drug-induced liver injury and 
depression/lipodystrophy) that led to discontinuation. NRTI and non-NRTI resistance-associated 
mutations were reported in 4/198 (2·0%) and 17/198 (8·6%) subjects, respectively, receiving 
BMS-986001, versus 0/99 and 1/99 subjects receiving TDF. BMS-986001 arms showed an 
apparent smaller decrease in lumbar spine and hip bone mineral density but greater accumulation 
of limb and trunk fat, subcutaneous and visceral adipose tissue, and increased total cholesterol 
compared with TDF. 
Interpretation 
BMS-986001 demonstrated similar efficacy to TDF; however, more subjects developed resistance 
to study drug(s) in BMS-986001 arms. A smaller bone mineral density decline was seen for BMS-
986001 versus TDF. However, gains in both peripheral and central fat accumulation were 
observed for BMS-986001. Bristol-Myers Squibb has discontinued its involvement in the 
development of BMS-986001, and future decisions on the development of BMS-986001 will be 
made by Oncolys BioPharma, Inc.  
Funding 
Bristol-Myers Squibb.  
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INTRODUCTION 
Nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are the backbone agents upon which 
most combination antiretroviral therapy (cART) for HIV is built. Current treatment guidelines 
recommend that cART regimens for treatment-naïve patients incorporate two NRTIs and one other 
active class of agent, such as an integrase inhibitor (INSTI) or a protease inhibitor (PI) with a 
pharmacokinetic enhancer (cobicistat or ritonavir).1,2  
Despite the widespread use of NRTIs in first-line treatment regimens, they are associated with 
toxicities, which can lead to long-term complications. These can include decreased bone mineral 
density (BMD),3 lipoatrophy,4,5 anaemia, pancreatitis,6,7 and hypersensitivity reaction.8 Several 
NRTIs, including didanosine, stavudine (d4T), and zidovudine, are not used routinely due to toxicities 
associated with mitochondrial (mt) dysfunction, namely peripheral neuropathy,9,10 lipoatrophy,4,5 
hepatic steatosis11, and metabolic acidosis12,13. Thus, there is a need for an NRTI with potent anti-
HIV-1 activity, a tolerability profile better than currently available NRTI agents, a long-term safety 
profile that is favourable in terms of BMD and renal function, and limited cross-resistance to existing 
NRTIs. 
BMS-986001 (also known as OBP-60)  is a thymidine analogue NRTI (an analogue of d4T) 
specifically designed to maintain the in vitro antiviral activity demonstrated by other NRTIs and 
minimise off-target effects that cause toxicities.14,15 In vitro experiments have shown that BMS-
986001 has potent antiviral activity and reduced mitochondrial toxicity compared with d4T.15,16 BMS-
986001 also shows reduced inhibition of host DNA polymerases14,15 and, in preclinical studies, has 
shown no evidence of bone or renal toxicity.17 Furthermore, BMS-986001 has demonstrable activity 
against most HIV-1 subtypes (Bristol-Myers Squibb, unpublished data, 2011) and against HIV-1 
isolates with certain NRTI resistance-associated mutations (RAMs), including K65R, L74V, and the 
Q151M constellation (without M184V).18 M184V induced a low-level decrease (2- to 3-fold) in viral 
susceptibility to BMS-986001.18 
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In a Phase 2a, dose-escalating, monotherapy study conducted for 10 days in treatment-experienced, 
HIV-1-infected, subjects who were not exposed to any antiretroviral treatment in the previous 3 
months, BMS-986001 demonstrated a median decrease in HIV-1 RNA from baseline of at least 1 
log10 copies per mL for all doses.19 These findings were used to support the design of this dose-
finding Phase 2b study, which assessed the efficacy and safety of three doses of BMS-986001 (100, 
200, and 400 mg once daily) versus tenofovir disoproxil fumarate (TDF 300 mg once daily), when co-
administered with efavirenz (EFV 600 mg once daily) and lamivudine (3TC 300 mg once daily) in 
treatment-naïve, HIV-1-infected subjects. A detailed assessment of bone, renal, metabolic and 
mitochondrial parameters was performed to assess the safety of BMS-986001.  
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METHODS 
Study design 
AI467003 was a Phase 2b, randomised, active-controlled, blinded-to-BMS-986001 dose trial carried 
out at 47 sites across South America, North America, South Africa, Australia, Asia, and Europe. 
This study was conducted in accordance with Good Clinical Practice (GCP), as defined by the 
International Conference on Harmonisation (ICH) and in accordance with the ethical principles 
underlying European Union Directive 2001/20/EC and the United States Code of Federal Regulations, 
Title 21, Part 50 (21CFR50). The study was conducted in compliance with the protocol. The protocol 
and any amendments, and the subject informed consent received Institutional Review 
Board/Independent Ethics Committee (IRB/IEC) approval/favourable opinion prior to initiation of the 
study. 
Participants 
Eligible subjects were treatment-naïve (defined as no current or previous exposure to an antiretroviral 
drug for more than 1 week), HIV-1-infected adults aged at least 18 years with plasma HIV-1 RNA 
greater than 5,000 copies per mL and CD4+ T-cell counts greater than 200 cells/mm3 at screening. 
Exclusion criteria included a history of phenotypic and/or genotypic drug resistance testing showing 
resistance to EFV, TDF, or 3TC, presence of hepatitis B surface antigen, hepatitis C virus antibody or 
RNA, history of abnormal liver transaminases (defined as greater than three times the upper limit of 
normal) at screening, and creatinine clearance less than 60 mL/min at screening. All subjects provided 
written informed consent in agreement with the Declaration of Helsinki principles.  
Outcomes 
Primary endpoints were the proportion of subjects with plasma HIV-1 RNA less than 50 copies per 
mL at Week 24 and the frequency of SAEs and AEs leading to discontinuation through Week 24. 
Secondary endpoints were proportion of subjects with plasma HIV-1 RNA less than 50 copies per mL 
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at Week 48 and the frequency of SAEs and AEs leading to discontinuation through Week 48. 
Additional secondary endpoints were change from baseline in CD4+ T-cell counts and the number of 
subjects with virologic failure who had virus exhibiting genotypic drug RAMs through Weeks 24 and 
48. 
Exploratory endpoints were assessment of the effect of BMS-986001 and TDF on change from 
baseline in mtDNA copy number, BMD, body fat distribution, fasting lipid profile, and renal function 
at Weeks 24 and 48. 
Procedures 
Study visits were completed at screening and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 32, 40, and 48 (or upon 
early termination) during the study. Plasma HIV-1 RNA levels were quantified by polymerase chain 
reaction using the Abbott m2000 RealTime System (Abbott Molecular, USA). Protocol-defined 
virologic failure was defined as confirmed plasma HIV-1 RNA at least 50 copies per mL at Week 24, 
or later (confirmed by second measurement within 4 weeks of the original sample), or virologic 
rebound (confirmed HIV-1 RNA at least 50 copies per mL at any time after prior confirmed 
suppression to less than 50 copies per mL, or confirmed increase in HIV-1 RNA greater than 1 log10 
copies per mL above the nadir level at any time [where nadir is at least 50 copies per mL]).    
Viral drug resistance testing was conducted at screening and in the event of confirmed PDVF, or at a 
minimum in the event of a confirmed plasma HIV-1 RNA measurement of at least 400 copies per mL 
at any time during the study (having previously achieved viral suppression [less than 50 copies per 
mL]) or discontinuation before achieving viral suppression after Week 8 with a last plasma HIV-1 
RNA measurement of at least 400 copies per mL. Genotypic and phenotypic resistance testing were 
performed using the GenoSure® MG (screening) and the Phenosense® GT (failure) assays (both 
Monogram Biosciences, South San Francisco, CA).  
Physical examinations, measurement of vital signs, and clinical laboratory evaluations were 
performed at selected times throughout the study, and subjects were closely monitored for adverse 
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events (AEs) and serious AEs (SAEs) throughout. AEs were coded according to MedDRA version 
16·0. The severity and relationship to study drug was assessed by the corresponding local 
investigator. Dual-energy X-ray absorptiometry (DXA) scans for measurement of BMD (hip and 
lumbar spine) and limb/trunk fat (whole body DXA scans) were performed at baseline and Weeks 24 
and 48, or upon early termination. Single slice computed tomography (CT) scans of the abdomen for 
measurement of visceral adipose tissue (VAT), subcutaneous adipose tissue (SAT) and total adipose 
tissue (TAT), were performed at baseline and Week 48, or upon early termination. For both DXA and 
CT scans, standardisation and blinded central reading were performed by BioClinica (Newtown, PA). 
Subcutaneous fat was obtained from a 3-mm skin punch biopsy from the lower abdomen or buttock 
area, from consenting subjects, for measurement of mtDNA content at baseline and Weeks 24 and 48, 
or upon early termination. The fat samples were separated from the overlying skin and stored in 
RNAlater® at -70oC freezer until batch processing at the end of the study. Quantification of mtDNA 
content was performed as described previously20 with an optimized DNA input of 1ng per 20uL 
reaction. Laboratory measurements, including CD4+ T-cell counts, and serum creatinine for 
estimation of creatinine clearance, were assessed. 
Randomisation and masking 
Eligible subjects were randomised 2:2:2:3 into four treatment arms: three treatment arms of BMS-
986001 (100, 200 or 400 mg once daily), and a reference treatment arm of TDF (300 mg once daily), 
each with a common background therapy of EFV (600 mg once daily) and 3TC (300 mg once daily). 
EFV and 3TC were selected owing to their known safety profiles, which allowed for reasonable 
assessment of the specific safety profile of BMS-986001 when used as a component of cART, and 
also their common use globally as first-line therapies. 
For subjects who met the protocol eligibility criteria, randomisation was performed using a computer-
generated code and stratified according to baseline viral load (HIV-1 RNA less than 100,000 copies 
per mL versus HIV-1 RNA at least 100,000 copies per mL). Both subjects and investigators remained 
blinded to BMS-986001 dose, but not allocation, through Week 48. BMS-986001 dose masking was 
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performed using once-daily dosing for all BMS-986001 treatment arms and similar looking placebo 
tablets. Sponsors were unblinded to BMS-986001 doses after the last subject had reached Week 24 
and subjects/investigators were unblinded after the last subject had reached Week 48. 
Statistical analysis 
This study was designed to estimate the effects of the randomised study medication. Thus, sample size 
considerations were based on the precision with which these effects can be estimated and not on the 
ability of the study to find statistically significant differences between treatment groups. Assuming a 
response rate of 80% , a target sample size of approximately 300 randomised subjects (67 per BMS-
986001 dose group and 100 in the TDF dose group) would provide a 95% exact binomial confidence 
interval (CI) that extends from 69% to 89% for a BMS-986001 arm (n=67) or from 71% to 87% for 
the TDF arm (n=100).   
The primary efficacy endpoint assessment used the FDA-defined snapshot algorithm that takes the 
last plasma HIV-1 RNA in the predefined Week 24 and 48 visit windows (+/- 6 weeks) to determine 
response. Thus, the modified intent-to-treat (mITT) population consisted of subjects who received at 
least one dose of BMS-986001 or TDF. The observed population consisted of subjects who received 
at least one dose of BMS-986001 or TDF, with plasma HIV-1 RNA measurements within the Week 
24 and 48 windows.   
The percent change from baseline in hip BMD was analysed using an analysis of covariance 
(ANCOVA) model with treatment group as a fixed effect and baseline value as a covariate. The 
analyses were conducted with the data limited to baseline and the time point of interest (Week 24 or 
Week 48). This was intended to increase the precision of the estimates by removing variability 
attributable to baseline differences. 
The trial is registered with ClinicalTrials.gov (NCT01489046) and the European Clinical Trials 
Database (EudraCT: 2011-003329-89). 
Role of funding source 
  10 
The sponsor of the study had a role in the study design, and data collection, analysis and 
interpretation, in conjunction with external study investigators. The first draft of the manuscript was 
prepared by a professional medical writer, paid for by the sponsor, and edited and revised by all 
authors. The corresponding author had full access to all the data in the study and had final 
responsibility for the decision to submit for publication.  
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RESULTS 
Recruitment into the study took place between January 25, 2012 and October 3, 2012. A total of 757 
subjects were screened, of which 301 were randomised and 297 treated (Figure 1). The majority of 
screening failures were due to failure to meet entry criteria; while not mutually exclusive, the most 
common reasons were a screening plasma HIV-1 RNA less than 5,000 copies per mL (238/456 
[52·2%]) and CD4+ T-cell count less than 200 cells/mm3 (79/456 [17·3%]). Of those receiving 
treatment, 40/198 (20·2%) across the BMS-986001 arms and 16/99 (16·1%) in the TDF arm, had 
discontinued from the study by the Week 48 database lock. Reasons for discontinuation included AEs, 
loss-to-follow-up, no longer meeting study criteria and poor/non-compliance.  
Baseline demographics and disease characteristics were similar across study arms (Table 1); median 
age was 31 years, two-thirds of subjects were male, and almost half were Black/African-American. 
Most subjects had HIV-1 subtypes C (38·4%), B (37·0%), or AE (20·2%). Median baseline HIV-1 
RNA and CD4+ T-cell count was 4·39 log10 copies per mL (17·5% had at least 100,000 copies per 
mL) and 307·0 cells/mm3 (8·4% had less than 200 cells/mm3), respectively. 
The FDA-defined snapshot algorithm (mITT population) and observed population criteria were used 
to determine the proportion of subjects with plasma HIV-1 RNA less than 50 copies per mL at Weeks 
24 and 48 for all study arms (Table 2). At Week 24 in the mITT population, 88%, 81% and 94% of 
subjects receiving BMS-986001 100, 200 and 400 mg once daily, respectively, and 89% receiving 
TDF had achieved HIV-1 RNA less than 50 copies per mL. In the observed population, 92%, 95% 
and 97% of subjects receiving BMS-986001 100, 200 and 400 mg once daily, respectively, and 97% 
receiving TDF achieved HIV-1 RNA less than 50 copies per mL. By Week 48, 75%, 81% and 89% of 
subjects receiving BMS-986001 100, 200 and 400 mg once daily, respectively, and 82% receiving 
TDF in the mITT population, and 96%, 100% and 100% of subjects receiving BMS-986001 100, 200 
and 400 mg once daily, respectively, and 96% of subjects receiving TDF in the observed population, 
had achieved HIV-1 RNA less than 50 copies per mL. CD4+ T-cell counts increased from baseline to 
Week 24 by a median of 157·0 (interquartile range [IQR] 104·0–236·0), 127·0 (IQR 67·0–192·0) and 
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139·0 (IQR 49·0–199·0) cells/mm3 for the BMS-986001 100, 200 and 400 mg once-daily arms, 
respectively, and 119·0 cells/mm3 (IQR 54·0–188·0) for the TDF arm. An increase in CD4+ T-cell 
count from baseline to Week 48 by a median of 171·0 (IQR 74·0–286·0), 139·5 (IQR 69·0–248·5) 
and 155·0 (IQR 97·0–225·0) cells/mm3 for the BMS-986001 100, 200 and 400 mg once-daily arms, 
respectively, and 147·5 cells/mm3 (IQR 79·0–281·0) for TDF was also observed. 
Through the Week 48 database lock, 18/198 (9·1%) subjects in the BMS-986001 arms and 4/99 
(4·0%) subjects in the TDF arm met on-study criteria for resistance testing. Of these, 16/18 and 1/4 
subjects, in the BMS-986001 arms and TDF arm, respectively, were successfully tested. Data from 
five additional subjects was received shortly after the Week 48 database lock. Combining both sets of 
data, it was found that 4/198 (2·0%) subjects in the BMS-986001 arms and 0/99 in the TDF arm had 
developed NRTI RAMs. M184V was the only NRTI RAM observed (2·0%). Additionally, 17/198 
(8·6%) subjects in the BMS-986001 arms and 1/99 (1·0%) in the TDF arm developed NNRTI RAMs. 
K103N was the most common NNRTI RAM observed (7·1%) (Table 3). Overall, the BMS-986001 
100 mg arm had the greatest numbers of NNRTI and NRTI RAMs compared with the BMS-986001 
200 mg and 400 mg arms, and the TDF arm. 
BMS-986001 was generally well tolerated through Week 48. Particular Grade 2–4-related AEs, such 
as skin/subcutaneous tissue disorders (BMS-986001, 6·1–12·3%; TDF, 4·0%), metabolic disorders 
(primarily high cholesterol) (BMS-986001, 1·5–7·6%; TDF, 1·0%) and gastrointestinal disorders 
(BMS-986001, 1·5–6·2%; TDF, 1·0%), were more frequently reported for BMS-986001 compared 
with TDF (Supplementary Table 1). SAEs were reported in 19/198 (9·6%) subjects across the BMS-
986001 and in 9/99 (9·1%) subjects for TDF (Supplementary Table 2). Two subjects had BMS-
986001-related SAEs: atypical drug eruption and thrombocytopenia. A female aged 49 years 
developed genital ulcers and episcleritis 7 days after initiating treatment and oral ulcers 5 days later, 
leading to hospitalisation. Ulcer swabs were PCR-negative for cytomegalovirus  and herpes simplex 
virus. The subject received acyclovir, xylocaine–epinephrine, and dexamethasone, and the SAE 
resolved. A male aged 25 years developed an asymptomatic decline in platelet count (without other 
haematological dyscrasias), which started 3 months and progressed during 1 year of treatment. The 
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SAE resolved without intervention after treatment completion. Two subjects in the TDF arm also had 
study drug-related SAEs (potential drug-induced liver injury and depression/lipodystrophy) that led to 
discontinuation. One non-study-related death occurred (pneumonia) in the BMS-986001 200 mg 
once-daily group. Grade 2–4 lab abnormalities were transient and mostly did not lead to 
discontinuation.  
Average change from baseline in lumbar spine BMD (calculated using baseline-adjusted ANCOVA 
[data not shown]) for BMS-986001 was −0·9% (CI −1·3, −0·5) and −1·4% (CI −1·9, −0·8) at Weeks 
24 and 48, respectively, compared with a roughly 2-fold lower result of −3·0% (CI −3·6, −2·4) and 
−3·2% (CI −4·1, −2·4) for TDF (Figure 2a). Similarly, average change from baseline in hip BMD for 
BMS-986001 was −0·5% (CI −0·8, −0·2) and −1·2% (CI −1·6, −0·75) at Weeks 24 and 48, 
respectively, compared with a roughly 3-fold lower result of −1·7% (CI −2·2, −1·2) and −3·0% (CI 
−3·7, −2·4) for TDF (Figure 2b). Concordant with the smaller declines in BMD for BMS-986001, the 
magnitudes of percentage changes from baseline for biomarkers of bone resorption, C-terminal 
telopeptide of type I collagen (CTx), and formation, serum type 1 procollagen N-terminal (P1NP), 
bone sialoprotein (B-SAP), osteocalcin, were lower in the BMS-986001 arms relative to TDF at 
Weeks 12, 24 and 48 (Supplementary Figure 1). Mean change in creatinine clearance at Week 48 
was 4·0 (standard error [SE] 3·0), 1·1 (SE 1·8), −1·6 (SE 2·7) mL/min for the BMS-986001 100, 200 
and 400 mg once-daily arms, respectively, and 0·048 (SE 1·9) mL/min for the TDF arm.  
DXA measurements showed  that mean percentage increase in limb fat at Week 24 across the BMS-
986001 100, 200 and 400 mg arms was 4·5% (SE 2·9), 2·3% (SE 1·8) and 10·0% (SE 3·0), 
respectively, which was higher compared with the 1·2% (SE 1·7) increase for TDF. Similarly, at 
Week 48 the BMS-986001 100, 200 and 400 mg arms reported greater increases in limb fat of 12·0% 
(SE 5·0), 8·0% (SE 2·9) and 15·8% (SE 4·7), respectively, compared with 2·1% (SE 1·9) for TDF. 
Trunk fat increase was also observed at Week 24 across the BMS-986001 100, 200 and 400 mg arms 
by a mean percentage of 2·3% (SE 2·9), 1·3% (SE 1·6) and 12·7% (SE 4·1) respectively, compared 
with 2·5% (SE 2·5) for TDF. At Week 48, the BMS-986001 100, 200 and 400 mg arms reported 
  14 
increases in trunk fat of 8·3% (SE 3·6), 7·0% (SE 2·6) and 18·4% (SE 6·2), respectively, compared 
with the lower 3·8% (SE 3·1) for TDF. 
Loss in baseline limb fat of at least 10% at Week 24 was reported in 6/53 (11·3% [95% CI 4·3, 
23·0]), 7/47 (14·9% [CI 6·2, 28·3]), and 6/53 (11·3% [CI 4·3, 23·0]) subjects  in the 100, 200, and 
400 mg BMS-986001 arms, respectively, compared with the slightly higher 13/69 (18·8% [CI 10·4, 
30·1]) subjects in the TDF arm. At Week 48, this was reported in 4/45 (8·9% [CI 2·5, 21·2]), 6/45 
(13·3% [CI 5·1, 26·8]), and 6/51 (11·8% [CI 4·4, 23·9]) subjects in the 100, 200, and 400 mg BMS-
986001 arms, respectively, compared with  the slightly higher 13/65 (20·0% [CI 11·1, 31·8]) subjects 
for TDF. Loss in baseline limb fat of at least 20% at Week 24 was reported in 4/53 (7·5% [CI 2·1, 
18·2]), 1/47 (2·1% [CI 0·1, 11·3]), 2/53 (3·8% [CI 0·5, 13·0]) subjects on BMS-986001 100, 200 and 
400 mg once-daily arms respectively, similar to the 4/69 (5·8% [CI 1·6, 14·2]) subjects receiving 
TDF. At Week 48, this was reported in 3/45 (6·7% [CI 1·4, 18·3]), 2/45 (4·4% [CI 0·5, 15·1]), 4/51 
(7·8 % [CI 2·2, 18·9]) subjects receiving BMS-986001 100, 200 and 400 mg once-daily respectively, 
similar to the 5/65 (7·7% [CI 2·5, 17·0]) subjects receiving TDF. 
CT scans showed greater gains in mean percentage SAT and VAT across the BMS-986001 arms 
(SAT, 11·1% [standard deviation, SD 37·5], 9·3% [SD 28·9] and 23·1% [SD 76·4] for the 100, 200 
and 400 mg once-daily arms; VAT, 12·5% [SD 45·8], 16·5% [SD 41·6] and 33·3% [SD 90·9] for the 
100, 200 and 400 mg once-daily arms), compared with TDF (SAT, –3·4% [SD 30·064]; VAT, 13·7% 
[SD 72·7]) at Week 48 (Supplementary Figure 2). The greatest changes from baseline in SAT and 
VAT occurred in the BMS-986001 400 mg arm. Mean change in mtDNA copy number (extracted 
from subcutaneous fat biopsies) at Week 48 was 3·9% ([SE 5·9], n=47), −1·0% ([SE 6·8], n=50) and 
−3·7% ([SE 6·4], n=55) for the BMS-986001 100, 200 and 400 mg once-daily arms, respectively, and 
−2·5% ([SE 5·6], n=72) for TDF. A numerically greater increase in total cholesterol was observed 
across the BMS-986001 arms (mean change from baseline in total cholesterol at Week 24 was 23·3 
[SE 3·5], 34·3 [3·5], 24·0 [3·8] mg/dL and at Week 48 was 33·7 [SE 5·2], 37·1 [SE 4·0] and 33·8 
[SE 4·5] mg/dL for the BMS-986001 100, 200 and 400 mg once-daily arms, respectively), compared 
with the TDF arm (14·5 [2·9] mg/dL at Week 24 and 23.0 [SE 3·1] mg/dL at Week 48). At Week 48, 
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mean ratios of total cholesterol to high-density lipoprotein-cholesterol were similar between the BMS-
986001 arms (3·5 [SD 1·0], 3·4 [SD 1·1], 3·3 [SD 0·9] for the BMS-986001 100, 200 and 400 mg 
once-daily arms, respectively) and TDF (3·6 [SD 1·3]) (baseline levels of cholesterol and 
triglycerides provided in Supplementary Table 3).  
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DISCUSSION 
The continued use of NRTIs as backbone agents for cART, despite their associated toxicity concerns, 
highlights the need to develop new NRTI agents with potent antiviral activity, improved toxicity 
profiles and limited cross-resistance to existing NRTIs. BMS-986001 is a thymidine analog NRTI (a 
novel analog of d4T) that was developed to have similar in vitro activity to existing NRTIs but with 
an improved toxicity profile.15,16 In this study, 24 weeks of treatment with BMS-986001 (100, 200, 
and 400 mg once daily) or TDF 300 mg once daily, each with a common background therapy of EFV 
600 mg once daily and 3TC 300 mg once daily, resulted in a similar number of subjects achieving 
plasma HIV-1 RNA less than 50 copies per mL. However, within the BMS-986001 arms, antiviral 
activity for the 400 mg arm was higher when compared with the 100 mg and 200 mg arms. At Week 
48, in the mITT population, BMS-986001 dose-dependent efficacy was observed, and the 400 mg arm 
showed the greatest efficacy across all treatment arms, including the TDF arm. 
A higher percent of subjects developed emergent resistance to study drug(s) across all the BMS-
986001 arms compared with the TDF arm; the BMS-986001 100 mg arm had the highest proportion 
of subjects who developed emergent resistance to study drug(s). We speculate that the lower 
intracellular half-life of the active triphosphate form of BMS-986001 (approximately 9·7 hours)21 
compared with the intracellular half-life of the active diphosphate form of TDF (>60 hours)22 may 
have led to the resistance pattern observed. Also, subjects randomized to receive BMS-986001 took 
six pills a day whereas subjects in the TDF arm took three pills a day. This difference in pill burden 
may have affected adherence, however this effect was not formally assessed. Importantly, the 
emergent resistance observed was primarily to EFV and 3TC. This is in line with results from a 
previous randomised trial (ACTG 5202), which evaluated the efficacy, safety and resistance profile of 
four regimens (ritonavir-boosted atazanavir or EFV, both combined with abacavir [ABC] + 3TC or 
TDF + emtricitabine [FTC]) in treatment-naïve subjects. In this trial, both NRTI and NNRTI RAMs 
were more frequently observed in subjects who received EFV compared with those who received 
ATV + RTV.23 In a separate randomised trial (SINGLE), which compared dolutegravir (DTG) + ABC 
+ 3TC and EFV + FTC + TDF, no subjects in the DTG + ABC + 3TC group had detectable antiviral 
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resistance whereas one TDF–associated mutation and four EFV-associated mutations were detected in 
the EFV–TDF–FTC group.24  
BMS-986001 was generally well tolerated through Week 48. Some Grade 2–4-related AEs were more 
frequently reported in the BMS-986001 arms compared with TDF, however no dose-related trends for 
the BMS-986001 arms were apparent.  
Given the importance of toxicity issues associated with NRTIs, including decreased BMD,3 renal 
dysfunction, lipoatrophy,4,5 dyslipidaemia, and mitochondrial toxicity,4,5 we evaluated each of these 
parameters during this study. Compared with the BMS-986001 arms, the decrease in lumbar spine and 
hip BMD in the TDF arm was ~2·5-fold greater. This observation is consistent with several other 
studies,25,26 which have shown a greater decrease in BMD when using TDF-based therapies, compared 
with other regimens. Reassuringly, changes in BMD observed with BMS-986001 were comparable 
with those seen with ABC (combined with 3TC and EFV)25 and recently with tenofovir alafenamide 
fumarate.27 Consistent with the lower declines in lumbar spine and hip BMD, the changes from 
baseline for biomarkers of bone resorption and formation were also lower for the BMS-986001 arms 
compared with TDF, suggesting that BMS-986001 has less pronounced effects on the bone. No 
appreciable changes in creatinine clearance were seen across any treatment arm at Week 48, although 
longer-term studies would be required to determine if larger changes occur with more prolonged use. 
Increases in limb and trunk fat were observed for all BMS-986001 and TDF arms, with the greatest 
gains observed in the BMS-986001 400 mg once-daily arm. Increases in SAT and VAT were seen 
mainly in the BMS-986001 arms, particularly the 400 mg once-daily arm, and not with TDF. The 
clinical significance of these gains in peripheral and central fat for BMS-986001, particularly for the 
400 mg once-daily arm, will require further study and mechanistic understanding given that visceral 
fat accumulation has been generally associated with both insulin resistance and cardiovascular 
disease.28 Furthermore, the fat accumulation observed after 48 weeks in this study is similar to that 
seen after 96 weeks in two other ART-initiation studies using either ABC/3TC or TDF/FTC.29,30 The 
loss of baseline limb fat (of at least 10%) reported in a small subset of subjects in this study was 
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generally low for the BMS-986001 arms and the loss of baseline limb fat (of at least 20%) and was 
similar to TDF. These data for BMS-986001 are reminiscent of findings from other studies with ABC 
or TDF-containing regimens.29,30 The clinical significance of the small differences in lipid levels 
between BMS-986001 and TDF is presently unclear and would require longer-term study.  
As BMS-986001 is an analogue of d4T, and d4T has been associated with mitochondrial toxicity,31 
changes in mtDNA copy number were monitored during this study. No meaningful changes from 
baseline in mtDNA copy number were observed, consistent with the lack of lipoatrophy reported, for 
BMS-986001. Similar observations were also made for TDF. 
There were several strengths in our study. The study was conducted across six continents and female 
subjects were well represented (34%). Resistance data, including those beyond the Week 48 database 
lock, was included within the analysis of the study. Additionally, thorough safety assessments (bone, 
metabolic, renal and mitochondrial safety) were performed as part of the study. However, there were 
also limitations in our study. Only 17·5% of subjects had baseline HIV-1 RNA of at least 100,000 
copies per mL, making it difficult to draw conclusions about this subset of subjects. This was also a 
partially-blinded study, with both subjects and investigators blinded to BMS-986001 dose, but not 
allocation. Adherence was also not formally assessed; therefore any potential effect of pill burden on 
the observed resistance profile could not be determined. Finally, a greater study size would be 
required to convincingly demonstrate non-inferior efficacy and safety of any dose of BMS-986001 to 
TDF.  
In conclusion, following 48 weeks of treatment, higher doses of BMS-986001 demonstrated similar 
efficacy to TDF (both combined with EFV + 3TC). BMS-986001 was generally well tolerated, with 
smaller declines in BMD noted across the BMS-986001 arms compared with TDF. No signals for 
mitochondrial toxicity or concerns about lipoatrophy were observed. However, more subjects 
developed resistance to study drugs in the BMS-986001 arms compared with TDF. Additionally, 
gains in both peripheral and central fat accumulation were seen in the BMS-986001 arms, especially 
with the 400 mg dose, which potentially raises concerns about insulin resistance and cardiovascular 
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disease. In light of these results in total, AI467-003 was terminated after the Week 48 secondary 
endpoint and Bristol-Myers Squibb has discontinued its involvement in the development of BMS-
986001. Any future decisions on the development of BMS-986001 will be made by Oncolys 
BioPharma, Inc, which owns the rights to the compound.   
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RESEARCH IN CONTEXT 
Evidence before this study  
A PubMed search using the terms, “mitochondrial toxicity” or “renal toxicity” or “bone mineral 
density” and “NRTI” provides substantial evidence of the toxicity concerns that are associated with 
long-term NRTI use. BMS-986001 is a novel analogue of d4T, structurally engineered to address the 
toxicities commonly attributed to the NRTI class, without altering the potency of the agent.  The 
present clinical study, designed based on findings from previous preclinical and clinical studies, 
investigated if BMS-986001 showed both potent antiviral activity and a superior safety profile as a 
component of cART when compared to a robust comparator arm. To select a relevant comparator 
arm, PubMed searches were performed with the terms, “A5202” or “GS-01-934” (an additional search 
for ““Study 934 group”” was also performed) or ““903 study group”” as these trials investigated 
robust and commonly used first-line regimens for treatment-naïve, HIV-1 infected subjects. Searches 
were restricted to articles published in English between 2003 and 2013. Of the 18 articles, the 
majority reported findings relating to the ACTG A5202 study (and sub studies, e.g. ACTG A5224) 
and two from the GS-01-934 trial and one from study GS-903. In all three trials, TDF was used as a 
component of cART. The ACTG A5202 study reported that virologic failure was significantly less 
likely and time to primary safety endpoint was shorter if subjects were assigned TDF-FTC compared 
to ABC-3TC. In study GS-01-934, EFV plus TDF-FTC was non-inferior to EFV plus zidovudine 
(ZDV)-3TC and superior with respect to virologic suppression, CD4 response and AEs leading to 
discontinuation. Finally, in study 903 TDF appeared to be associated with better lipid profiles and less 
lipodystrophy compared with d4T. Thus, these studies facilitated in selecting TDF as a cART 
component of the comparator arm in the present study.  
Added value of this study 
This Phase 2b study investigated the efficacy and safety profile of BMS-986001 as a component of 
cART. Higher doses of BMS-986001 showed greater efficacy (both combined with EFV and 3TC). 
BMS-986001 was generally well tolerated with no signals for mitochondrial toxicity or concerns 
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about lipoatrophy, and with smaller declines in BMD compared with TDF. However, more subjects 
developed resistance to study drugs in the BMS-986001 arms compared with TDF and some gains in 
both peripheral and central fat accumulation were seen. 
Implications of all the available evidence 
This study demonstrates that small structural changes can positively influence the safety profile of an 
antiretroviral therapy, but these structural alterations need optimisation so as not to alter other drug 
characteristics important to long-term cART use. Although further development of BMS-986001 is 
not being pursued at this time, the strategy of introducing structural changes to existing NRTIs may 
improve the overall clinical profile of such agents.  
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TABLES AND FIGURES 
Table 1: Baseline demographics and disease characteristics 
 
BMS-986001 + EFV + 3TC 
 
TDF + EFV + 
3TC 
100 mg once 
daily 
N=65 
200 mg once 
daily 
N=67 
400 mg once 
daily 
N=66 
300 mg  
once daily 
N=99 
Median age, years (range) 31 (18–64) 32 (18–53) 34 (19–57) 29 (18–61) 
Gender, n (%) 
Male 
Female 
 
43 (66%) 
22 (34%) 
 
42 (63%) 
25 (37%) 
 
41 (62%) 
25 (38%) 
 
70 (71%) 
29 (29%) 
Race, n (%) 
Black 
Asian 
White 
Other* 
 
31 (48%) 
15 (23%) 
11 (17%) 
8 (12%) 
 
32 (48%) 
15 (22%) 
10 (15%) 
10 (15%) 
 
35 (53%) 
14 (21%) 
7 (11%) 
10 (15%) 
 
40 (40%) 
27 (27%) 
15 (15%) 
17 (17%) 
Baseline body mass index, 
kg/m2, median 
23.9 23.8 22.3 23.3 
Baseline adipose tissue, 
cm2, median 
Subcutaneous adipose 
tissue 
Total adipose tissue 
Visceral adipose tissue 
 
 
 
110.7 
 
181.0 
37.4 
 
 
89.6 
 
141.9 
33.4 
 
 
68.1 
 
100.3 
32.2 
 
 
71.0 
 
107.5 
33.2 
HIV-1 subtype, n (%) 
AE 
B 
 
14 (22%) 
28 (43%) 
 
13 (19%) 
22 (33%) 
 
8 (12%) 
24 (36%) 
 
25 (25%) 
36 (36%) 
  29 
C 
Other 
22 (34%) 
1 (2%) 
30 (45%) 
2 (3%) 
29 (44%) 
5 (8%) 
33 (33%) 
5 (5%) 
Baseline viral load (HIV-1 
RNA) 
Median, log10 copies per 
mL  
Proportion of subjects 
with ≥100,000 copies 
per mL, n (%) 
 
 
4·34 
 
11 (17%) 
 
 
4·43 
 
12 (18%) 
 
 
4·46 
 
12 (18%) 
 
 
4·38 
 
17 (17%) 
Baseline CD4+ T-cell count 
Median, cells/mm3  
 
Proportion of subjects 
with <200 cells/mm3, n 
(%) 
290 
 
 
6 (9%) 
325 
 
 
3 (5%) 
330 
 
 
4 (6%) 
301 
 
 
12 (12%) 
3TC, lamivudine; EFV, efavirenz; TDF, tenofovir disoproxil fumarate.   
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Table 2: Proportion of subjects with plasma HIV-1 RNA <50 copies/mL at Weeks 24 and 48: FDA-
defined snapshot algorithm (mITT population) and observed population analysis 
Parameter, 
n (%) 
BMS-986001 + EFV + 3TC TDF + EFV + 3TC 
100 mg 
once daily 
N=65 
200 mg 
once daily 
N=67 
400 mg 
once daily 
N=66 
300 mg 
once daily 
N=99 
mITT analysis (FDA Snapshot algorithm) 
W
ee
k 
24
 
HIV-1 RNA <50 cop/mL 57 (88%) 54 (81%) 62 (94%) 88 (89%) 
HIV-1 RNA ≥50 c/mL* 8 (12%) 9 (13%) 4 (6%) 7 (7%) 
No virological data at 
Week 24     
Discontinued due to 
AE or death 0 4 (6%) 0 2 (2%) 
Discontinued for 
other reason 0 0 0 2 (2%) 
Missing data during 
window but on-study 0 0 0 0 
W
ee
k 
48
 
HIV-1 RNA <50 c/mL 49 (75%) 54 (81%) 59 (89%) 81 (82%) 
HIV-1 RNA ≥50 c/mL* 12 (19%) 8 (12%) 3 (5%) 8 (8%) 
No virological data at 
Week 48     
Discontinued due to 
AE or death 0 5 (7%) 2 (3%) 4 (4%) 
Discontinued for 
other reason 4 (6%) 0 1 (1·5%) 6 (6%) 
Missing data during 
window but on-study 0 0 1 (1·5%) 0 
Observed analysis 
W
ee
k 
24
 
Observed population, N 62 57 64 91 
HIV-1 RNA <50 
copies/mL, n (%) 57 (92%) 54 (95%) 62 (97%) 88 (97%) 
W
ee
k 
48
 
Observed population, N 51 54 59 84 
HIV-1 RNA <50 
copies/mL, n (%) 49 (96%) 54 (100%) 59 (100%) 81(96%) 
 
*Virological failure 
3TC, lamivudine; EFV, efavirenz; TDF, tenofovir disoproxil fumarate.  
  31 
Table 3: Treatment-emergent resistance profile 
 BMS-986001 + EFV + 3TC TDF + EFV + 3TC 
100 mg 
once daily 
N=65 
200 mg 
once daily 
N=67 
400 mg 
once daily 
N=66 
300 mg 
once daily 
N=99 
Met criteria for 
resistance testing, n* 10 6 2 4 
Genotype determinable, 
n* 10 4 2 1 
Emergent resistance/reduced susceptibility to study drugs (includes recent data post-DBL) 
NNRTI RAM, n (%) 9 (14%) 4 (6%) 4 (6%)† 1 (1%)‡ 
K103N, n 8 3 3 1 
V106M, n 1 1 0 0 
Y188C, n 1 0 0 0 
G190A, n 1 0 1 0 
NRTI RAM, n (%) 3 (5%) 0 1 (2%) 0 
M184V, n 3 0 1 0 
* Minimum criteria for resistance testing: (1) Confirmed HIV-1 RNA >400 copies/mL after achieving viral 
suppression (HIV-1 RNA <50 copies/mL) (2) Discontinuation from study prior to achieving viral suppression after 
Week 8, with last plasma HIV-1 RNA >400 copies/mL. Based on all data available through the Week 48 database 
lock (DBL). † Two patients developed EFV RAM (Week 40 and Week 12) and provided data after DBL. ‡ One 
patient developed EFV RAM (Week 32) and provided data after DBL. Additionally, one patient in the 100 mg 
(Week 56) and one patient in the 400 mg (Week 56) arms developed EFV RAM and provided data after DBL. 
 
3TC, lamivudine; EFV, efavirenz; RAM, resistance associated mutation; TDF, tenofovir disoproxil fumarate.  
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Figure legends 
 
Figure 1: Study enrolment and randomization  
3TC, lamivudine; EFV, efavirenz; TDF, tenofovir disoproxil fumarate. 
 
 
Figure 2: Mean percent change in BMD by DXA from baseline to Week 24 and 48  
BMD, bone mineral density; QD, once daily; SE, standard error of the mean. 
